Autism Spectrum Disorder is a disorder that makes learning, socializing and daily living much more challenging for affected children and adults because of their atypical behaviors. A few examples of these behaviors are repetitive movements, impulsive actions, inability to communicate in a social setting, and many more. There is a stigma behind autism that is caused by those who are not well informed on the disorder. These people lack information, and in the past, it was assumed that the disorder is caused by "bad parenting." The parents are then afraid of social shame brought upon them by their child and neglect or avoid a diagnosis for their child's disorder. This becomes a vicious cycle that has negative effects on the affected individuals and their loved ones. Neglect of a diagnosis may also be caused by misinformation interpreted by the parents as their child develops. The parents do not realize this child developing outside of normal behavioral patterns. Years of research have been done to attempt to alleviate the symptoms of autism and cure the disorder. The Autism and Asperger's Program at ASU has developed a year-long dietary plan that increases supplementation to alleviate nutritional deficiencies in participants with autism. These deficiencies include vitamins, minerals, essential fatty acids, sulfate, carnitine, and digestive enzymes such as sucrase, maltase, and lactase. The participants were also put on a gluten-free casein-free diet toward the end of the study. To test the effectiveness of the treatment, the Severity of Autism Scale (SAS) and Social Responsiveness Scales (SRS) were used. The SAS tested the overall severity of ASD participants by rating them from one to ten, ten being "very severe" in terms of ASD symptoms. The results of this scale were compared at the beginning of the study (day 0) and at the end of the study (day 365). The SRS tested the social responsiveness of participants in the form of overall SRS and five subscales that included awareness, cognition, communication, motivation, and mannerisms. These results were also compared at the beginning and end of the study. After analysis of the data, there seemed to be no correlation between age and severity of autism/social responsiveness of participants. There was also no statistically significant data to suggest that there was a correlation between gender and severity of autism/social responsiveness of participants. However, there was statistically significant evidence that the treatment group did improve over the non-treatment/delayed treatment group in both the SAS and SRS. Neither age nor gender had a significant effect on the effectiveness of the treatment. These positive findings suggest that the integrated dietary
utritional therapy was beneficial, and future research on dietary treatments for autism and other disorders is recommended. This may also further discoveries of affected epigenomes with regards to nutritional treatments in disorders like ASD. The epigenome is the methylation and demethylation of the genome that mediates gene expression.

Vitamins and minerals are, by definition, essential substances that are necessary for good health, and needed by every cell and organ to function appropriately. A deficiency of any one vitamin or mineral can be very serious. Although a very healthy diet rich in vegetables, fruits, and protein can provide sufficient amounts of most vitamins and minerals, many people do not consume an adequate diet. During pregnancy, there is an increased need for vitamins and minerals to promote a healthy pregnancy and a healthy baby. Prenatal supplements are intended to supplement a normal diet to ensure that adequate amounts of vitamins and minerals are consumed. The US Food and Drug Administration (FDA) has established Recommended Dietary Allowances for total vitamin/mineral intake from food and supplements, but they have not established recommendations for prenatal supplements. Therefore, there is a very wide variation in the content and quality of prenatal supplements. Many prenatal supplements contain only minimal levels of some vitamins and few or no minerals, in order to minimize cost and the number of pills. This results in insufficient vitamin/mineral supplementation for many women, and hence does not fully protect them or their children from pregnancy complications and health problems. Therefore, we have created our own set of recommendations for prenatal supplements. Our recommendations are based primarily on four sources: 1) FDA's Recommended Daily Allowances for pregnant women, which are estimated to meet the needs of 97.5% of healthy pregnant women. 2) FDA's Tolerable Upper Limit, which is the maximum amount of vitamins/minerals that can be safely consumed without any risk of health problems. 3) National Health and Nutrition Examination Survey (NHANES), which evaluates the average intake of vitamins and minerals by women ages 20-40 years in the US 4) Research studies on vitamin/mineral deficiencies or vitamin/mineral supplementation during pregnancy, and the effect on pregnancy, birth, and child health problems. In summary, the RDA establishes minimum recommended levels of vitamin/mineral intake from all sources, and the NHANES establishes the average intake from foods. The difference is what needs to be consumed in a supplement, on average. However, since people vary greatly in the quality of their diet, and since most vitamins and minerals have a high Tolerable Upper Limit, we generally recommend more than the difference between the RDA and the average NHANES. Vitamins generally have a larger Tolerable Upper Limit than do minerals. So, we recommend that prenatal vitamin/mineral supplements contain 100% of the RDA for most vitamins, and about 50% of the RDA for most minerals. However, based on additional research studies described below, in some cases we vary our recommendations from those averages.

This research investigates the whether dietary and nutritional treatments will improve some of the symptoms of autism. This treatment includes a combination of 6 nutritional and dietary treatments, which are vitamins/minerals, essential fatty acids, Epsom salts, carnitine, digestive enzymes, and healthy gluten-free, casein-free diet. 55 participants were involved in this study; 28 participants are in the Treatment Group and 27 participants in the Delayed Group. Data from the PDD-BI form, the ADOS form, the CARS form and the professional SAS form will be used in this thesis project for analyses. Factors analyzed are age, gender and severity [initial professional SAS data] and then correlating these factors with data from PDD-BI (autism composite score and each subscale), ADOS and CARS. The data analyses show that changing the dietary and nutritional needs of children/adults with autism improves the symptoms of autism (as rated by the PDD-BI) by approximately 22% in the treatment group vs. 3% in the non-treatment group, p<0.001. Overall, these results also suggest that the treatment is equally beneficial for males and females of varying age (young children to adult) and of all severity levels.

This is a study of the adaptive behaviors of individuals with Autism Spectrum Disorder using the Vineland II Adaptive Behavioral Scale (VABS-II). This scale was used to determine the overall functioning level of individuals with Autism Spectrum Disorder at the beginning, and will be used at the end, of a year-long study beginning at Arizona State University. This larger study is determining what the effects are, if any, of a combination of nutritional and dietary treatments in individuals with Autism Spectrum Disorder. However, this paper only examines the VABS-II results of forty-three participants in the study, as well as their hand-grip strength. It was found that individuals with Autism Spectrum Disorder are substantially delayed in all four domains (communication, daily living skills, social skills, and motor skills) of adaptive behaviors measured by the VABS-II, particularly in communication. This study will be completed in May 2013, when it will be determined what the effects of these treatments are, if any.

Introduction: A number of previous studies examined a possible association of toxic metals and autism, and over half of those studies suggest that toxic metal levels are different in individuals with Autism Spectrum Disorders (ASD). Additionally, several studies found that those levels correlate with the severity of ASD.

Methods: In order to further investigate these points, this paper performs the most detailed statistical analysis to date of a data set in this field. First morning urine samples were collected from 67 children and adults with ASD and 50 neurotypical controls of similar age and gender. The samples were analyzed to determine the levels of 10 urinary toxic metals (UTM). Autism-related symptoms were assessed with eleven behavioral measures. Statistical analysis was used to distinguish participants on the ASD spectrum and neurotypical participants based upon the UTM data alone. The analysis also included examining the association of autism severity with toxic metal excretion data using linear and nonlinear analysis. “Leave-one-out” cross-validation was used to ensure statistical independence of results.

Results and Discussion: Average excretion levels of several toxic metals (lead, tin, thallium, antimony) were significantly higher in the ASD group. However, ASD classification using univariate statistics proved difficult due to large variability, but nonlinear multivariate statistical analysis significantly improved ASD classification with Type I/II errors of 15% and 18%, respectively. These results clearly indicate that the urinary toxic metal excretion profiles of participants in the ASD group were significantly different from those of the neurotypical participants. Similarly, nonlinear methods determined a significantly stronger association between the behavioral measures and toxic metal excretion. The association was strongest for the Aberrant Behavior Checklist (including subscales on Irritability, Stereotypy, Hyperactivity, and Inappropriate Speech), but significant associations were found for UTM with all eleven autism-related assessments with cross-validation R² values ranging from 0.12–0.48.

Background: Autism spectrum disorders (ASD) are complex neurobiological disorders that impair social interactions and communication and lead to restricted, repetitive, and stereotyped patterns of behavior, interests, and activities. The causes of these disorders remain poorly understood, but gut microbiota, the 1013 bacteria in the human intestines, have been implicated because children with ASD often suffer gastrointestinal (GI) problems that correlate with ASD severity. Several previous studies have reported abnormal gut bacteria in children with ASD. The gut microbiome-ASD connection has been tested in a mouse model of ASD, where the microbiome was mechanistically linked to abnormal metabolites and behavior. Similarly, a study of children with ASD found that oral non-absorbable antibiotic treatment improved GI and ASD symptoms, albeit temporarily. Here, a small open-label clinical trial evaluated the impact of Microbiota Transfer Therapy (MTT) on gut microbiota composition and GI and ASD symptoms of 18 ASD-diagnosed children.

Results: MTT involved a 2-week antibiotic treatment, a bowel cleanse, and then an extended fecal microbiota transplant (FMT) using a high initial dose followed by daily and lower maintenance doses for 7–8 weeks. The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain. Improvements persisted 8 weeks after treatment. Similarly, clinical assessments showed that behavioral ASD symptoms improved significantly and remained improved 8 weeks after treatment ended. Bacterial and phage deep sequencing analyses revealed successful partial engraftment of donor microbiota and beneficial changes in the gut environment. Specifically, overall bacterial diversity and the abundance of Bifidobacterium, Prevotella, and Desulfovibrio among other taxa increased following MTT, and these changes persisted after treatment stopped (followed for 8 weeks).

Conclusions: This exploratory, extended-duration treatment protocol thus appears to be a promising approach to alter the gut microbiome and virome and improve GI and behavioral symptoms of ASD. Improvements in GI symptoms, ASD symptoms, and the microbiome all persisted for at least 8 weeks after treatment ended, suggesting a long-term impact.